As­traZeneca CEO So­ri­ot is over­see­ing a top ex­ec team over­haul in move to in­te­grate Med­Im­mune in a sweep­ing re­struc­tur­ing

As­traZeneca CEO Pas­cal So­ri­ot pos­es for a pho­to­graph fol­low­ing a tele­vi­sion in­ter­view late last year Bloomberg

EX­CLU­SIVE — The on­go­ing R&D re­or­ga­ni­za­tion at As­traZeneca is claim­ing a group of se­nior ex­ec­u­tives in the com­pa­ny’s US R&D or­ga­ni­za­tion as As­traZeneca ab­sorbs its big sub­sidiary Med­Im­mune in­to a new­ly re­vamped glob­al or­ga­ni­za­tion.

The phar­ma gi­ant is han­dling fresh ex­its from Bahi­ja Jal­lal’s se­nior lead­er­ship team at As­traZeneca’s Med­Im­mune sub­sidiary — up un­til her de­par­ture a few weeks ago to take the CEO’s job at Im­muno­core in the UK, sources fa­mil­iar with the lat­est moves tell me. More de­par­tures are ex­pect­ed. And cur­rent Med­Im­mune ex­ecs have been spread­ing the word that the sub­sidiary will soon end its 11-year run as a sep­a­rate or­ga­ni­za­tion as the com­pa­ny re­or­ga­nizes un­der two pre­vi­ous­ly an­nounced main R&D ban­ners, split­ting Med­Im­mune’s large mol­e­cule work be­tween two dis­ease-spe­cif­ic or­ga­ni­za­tions.

The re­or­ga­ni­za­tion has sparked in­tense ru­mors about which re­search groups will come out on top and which will be rel­e­gat­ed to the side­lines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.